Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA)
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
February 17, 1999
January 31, 2025
c6678a1b-ae2a-4f48-92c5-5c50a3029502
Related Documents
Possible Dioxin/PCB Contamination of Drug and Biological Products
Guidance DocumentAugust 23, 1999Center for Drug Evaluation and Research
Consumer-Directed Broadcast Advertisements: Guidance for Industry
Guidance DocumentAugust 1, 1999Center for Drug Evaluation and Research
Developing Medical Imaging Drug and Biological Products Part 3: Design, Analysis, and Interpretation of Clinical Studies
Guidance DocumentJune 22, 2004Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox